...
首页> 外文期刊>Pathology oncology research: POR >Clinical significance of ephrin (eph)-A1, -A2, -a4, -a5 and -a7 receptors in pancreatic ductal adenocarcinoma.
【24h】

Clinical significance of ephrin (eph)-A1, -A2, -a4, -a5 and -a7 receptors in pancreatic ductal adenocarcinoma.

机译:ephrin(eph)-A1,-A2,-a4,-a5和-a7受体在胰腺导管腺癌中的临床意义。

获取原文
获取原文并翻译 | 示例
           

摘要

Ephrin (Eph) receptors have been reported to be frequently overexpressed in a wide variety of cancer types, being associated with tumor growth, invasion, metastasis and angiogenesis. The aim of the present study was to evaluate the clinical significance of Eph-A1, -A2, -A4, -A5 and -A7 expression in pancreatic ductal adenocarcinoma. Eph-A1, -A2, -A4, -A5 and -A7 expression and staining intensity were assessed immunohistochemically in tumoral samples of 67 pancreatic adenocarcinoma patients and were statistically analyzed in relation to clinicopathological characteristics, tumor proliferative capacity and patients' survival. Eph receptors were abundantly expressed in pancreatic ductal adenocarcinoma cases examined. Eph-A1 staining intensity was significantly associated with tumor size (pT, p = 0.008) and tumor histopathological stage (pStage, p = 0.012). Eph-A2 expression was significantly associated with patients' age (p = 0.007), while Eph-A4 and Eph-A5 with tumor proliferative capacity (p = 0.019 and p = 0.011, respectively). Pancreatic adenocarcinoma patients with moderate/intense Eph-A5 or Eph-A7 staining presented significantly shorter survival times compared to those with negative/mild one (log-rank test, p = 0.024 and p = 0.009, respectively). Multivariate analysis identified Eph-A5 and Eph-A7 staining intensity as independent prognostic factors (p = 0.048 and p = 0.004, respectively). In conclusion, the present study revealed that Eph receptors were associated with pancreatic cancer characteristics, supporting evidence for their potential clinical application in management and prognosis of pancreatic adenocarcinoma patients.
机译:据报道,Ephrin(Eph)受体在多种癌症类型中经常过表达,与肿瘤生长,侵袭,转移和血管生成有关。本研究的目的是评估胰腺导管腺癌中Eph-A1,-A2,-A4,-A5和-A7表达的临床意义。用免疫组织化学方法对67例胰腺腺癌患者的肿瘤样本中Eph-A1,-A2,-A4,-A5和-A7的表达和染色强度进行了评估,并对其临床病理特征,肿瘤增殖能力和患者生存率进行了统计学分析。 Eph受体在胰腺导管腺癌病例中大量表达。 Eph-A1染色强度与肿瘤大小(pT,p = 0.008)和肿瘤组织病理学阶段(pStage,p = 0.012)显着相关。 Eph-A2的表达与患者年龄显着相关(p = 0.007),而Eph-A4和Eph-A5则具有肿瘤增生能力(分别为p = 0.019和p = 0.011)。 Eph-A5或Eph-A7中度/强染色的胰腺腺癌患者的生存时间显着短于阴性/轻度患者(对数秩检验,分别为p = 0.024和p = 0.009)。多变量分析将Eph-A5和Eph-A7染色强度确定为独立的预后因素(分别为p = 0.048和p = 0.004)。总之,本研究表明,Eph受体与胰腺癌的特征有关,为它们在胰腺腺癌患者的治疗和预后中的潜在临床应用提供了证据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号